Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity.
Erythropoietin (rHuEPO) therapy has been shown to be beneficial in preventing and treating anaemia of prematurity and to decrease the need for blood transfusions. There is, however, only scanty data on the effect of rHuEPO therapy on iron metabolism. We studied 29 preterm infants (age 34 +/- 14 days) who were randomly assigned to receive either rHuEPO 900 U kg-1 week-1 with 6 mg kg-1 day-1 of iron for 4 weeks (n = 15) or no therapy. The following parameters were evaluated and compared between and within groups at the beginning, during and at the end of the study: Haematocrit (SI), reticulocytes (10(9) micrograms l-1), serum ferritin (microgram 1-1) and iron (mumol l-1). The results were as follows. At the baseline, erythropoietin levels were similar in both groups: 7.2 +/- 5.6 versus 6.2 +/- 3.2 mU ml-1 (NS). In the treated infants the haematocrit remained stable during the study and was significantly higher than in the control group by the end of the study: 0.34 +/- 0.03 versus 0.28 +/- 0.05 (p = 0.001). rHuEPO therapy increased the reticulocyte count from 130 +/- 70 to 430 +/- 200 (p = 0.0002). However, rHuEPO therapy depleted both serum ferritin and iron levels from 321 +/- 191 to 76 +/- 58 micrograms l-1 (p = 0.04) and from 18 +/- 5 to 13 +/- 4 mumol l-1 (p = 0.03), respectively. We conclude that rHuEPO therapy prevented anaemia and its sequelae; however, serum ferritin and iron levels were depleted. We suggest that the effect of rHuEPO may be further increased by higher iron supplementation.
Bader
D
D
Department of Neonatology, Bnai-Zion Medical Centre, Technion, Israel Institute of Technology, Haifa, Israel.
Blondheim
O
O
Jonas
R
R
Admoni
O
O
Abend-Winger
M
M
Reich
D
D
Lanir
A
A
Tamir
A
A
Eldar
I
I
Attias
D
D
D000751:Anemia, Neonatal / Q000097:blood / Q000628:therapy*; D001835:Body Weight; D003131:Combined Modality Therapy; D004921:Erythropoietin / Q000627:therapeutic use*; D005293:Ferritins / Q000097:blood*; D005296:Ferrous Compounds / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood / Q000628:therapy*; D019102:Infant, Very Low Birth Weight; D007501:Iron / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use*; D017701:Reticulocyte Count
D005296:Ferrous Compounds; D011994:Recombinant Proteins; D004921:Erythropoietin; D005293:Ferritins; D007501:Iron